Palmidrol

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Palmidrol
Accession Number
DB14043
Type
Small Molecule
Groups
Experimental, Nutraceutical
Description

A cannabinoid receptor-inactive eCB-related molecule used as prophylactic in helping to prevent respiratory viral infection. Palmidrol is available for human use as a supplement (400 mg capsules) and as food for medical purposes In Italy and Spain (300 mg and 600 mg tablets).

Structure
Thumb
Synonyms
  • Hydroxyethylpalmitamide
  • Monoethanolamine palmitic acid amide
  • N-(2-Hydroxyethyl)palmitamide
  • N-hexadecanoylethanolamine
  • N-palmitoylethanolamine
  • palmidrolum
  • Palmitamide MEA
  • Palmitic acid monoethanolamide
  • Palmitinsaeure-beta-hydroxyethylamid
  • Palmitoyl ethanolamide
  • Palmitoyl-EA
  • Palmitoylethanolamide
  • PEA
International/Other Brands
Palmdrol prodes
Categories
UNII
6R8T1UDM3V
CAS number
544-31-0
Weight
Average: 299.4919
Monoisotopic: 299.282429433
Chemical Formula
C18H37NO2
InChI Key
HXYVTAGFYLMHSO-UHFFFAOYSA-N
InChI
InChI=1S/C18H37NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-18(21)19-16-17-20/h20H,2-17H2,1H3,(H,19,21)
IUPAC Name
N-(2-hydroxyethyl)hexadecanamide
SMILES
CCCCCCCCCCCCCCCC(=O)NCCO

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Palmidrol.Investigational
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Palmidrol is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Palmidrol is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Palmidrol is combined with 5-androstenedione.Experimental, Illicit
AbciximabPalmidrol may increase the anticoagulant activities of Abciximab.Approved
AcebutololPalmidrol may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Palmidrol is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Palmidrol is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolPalmidrol may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
AcetaminophenThe risk or severity of adverse effects can be increased when Palmidrol is combined with Acetaminophen.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Palmidrol is combined with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Palmidrol.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Palmidrol.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Palmidrol is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Palmidrol is combined with Aldosterone.Experimental, Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Palmidrol is combined with Alendronic acid.Approved
AliskirenPalmidrol may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Palmidrol.Experimental
AlprenololPalmidrol may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Palmidrol.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Palmidrol is combined with Amcinonide.Approved
AmikacinPalmidrol may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Investigational, Vet Approved
AmiloridePalmidrol may decrease the antihypertensive activities of Amiloride.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Palmidrol is combined with Aminosalicylic Acid.Approved
AmiodaronePalmidrol may decrease the antihypertensive activities of Amiodarone.Approved, Investigational
AncrodPalmidrol may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Palmidrol.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Palmidrol is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Palmidrol is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Palmidrol is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Palmidrol.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Palmidrol is combined with Antipyrine.Approved, Investigational
Antithrombin III humanPalmidrol may increase the anticoagulant activities of Antithrombin III human.Approved
AntrafenineThe risk or severity of adverse effects can be increased when Palmidrol is combined with Antrafenine.Approved
ApixabanPalmidrol may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Palmidrol.Investigational
ApramycinPalmidrol may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Palmidrol.Approved, Investigational
ArbekacinPalmidrol may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinPalmidrol may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanPalmidrol may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololPalmidrol may decrease the antihypertensive activities of Arotinolol.Investigational
AsenapinePalmidrol may decrease the antihypertensive activities of Asenapine.Approved
AtamestaneThe risk or severity of adverse effects can be increased when Palmidrol is combined with Atamestane.Investigational
AtenololPalmidrol may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Palmidrol.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Palmidrol.Approved
Azficel-TThe risk or severity of adverse effects can be increased when Palmidrol is combined with Azficel-T.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Palmidrol.Approved, Investigational
AzosemideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Palmidrol.Investigational
BalsalazideThe risk or severity of adverse effects can be increased when Palmidrol is combined with Balsalazide.Approved, Investigational
BecaplerminPalmidrol may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Palmidrol is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololPalmidrol may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinPalmidrol may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Palmidrol is combined with Benazepril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Palmidrol.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Palmidrol.Approved
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Palmidrol.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Palmidrol.Withdrawn
BenzthiazideThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Palmidrol.Approved
BenzydamineThe risk or severity of adverse effects can be increased when Benzydamine is combined with Palmidrol.Approved
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Palmidrol.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Palmidrol is combined with Betamethasone.Approved, Vet Approved
BetaxololPalmidrol may decrease the antihypertensive activities of Betaxolol.Approved, Investigational
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Palmidrol.Approved, Investigational
BevantololPalmidrol may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Palmidrol.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Palmidrol.Approved, Investigational
BisoprololPalmidrol may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinPalmidrol may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololPalmidrol may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Palmidrol is combined with Bromfenac.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Palmidrol.Investigational
BucindololPalmidrol may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Palmidrol is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Palmidrol is combined with Bufexamac.Approved, Experimental
BufuralolPalmidrol may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Palmidrol.Experimental
BumetanideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Palmidrol.Approved
BupranololPalmidrol may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Palmidrol.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Palmidrol.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Palmidrol is combined with Candoxatril.Experimental
CapsaicinThe risk or severity of adverse effects can be increased when Palmidrol is combined with Capsaicin.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Palmidrol is combined with Captopril.Approved
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Palmidrol.Experimental, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Palmidrol.Approved
CarprofenThe risk or severity of adverse effects can be increased when Palmidrol is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololPalmidrol may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolPalmidrol may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Palmidrol.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Palmidrol is combined with Celecoxib.Approved, Investigational
CeliprololPalmidrol may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinPalmidrol may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Palmidrol.Approved, Investigational, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Palmidrol.Approved, Vet Approved
ChlorphenesinThe risk or severity of adverse effects can be increased when Palmidrol is combined with Chlorphenesin.Approved, Vet Approved, Withdrawn
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Palmidrol.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Palmidrol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Palmidrol is combined with Choline magnesium trisalicylate.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Palmidrol is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Palmidrol is combined with Cilazapril.Approved
CimicoxibThe risk or severity of adverse effects can be increased when Palmidrol is combined with Cimicoxib.Investigational
CinoxacinPalmidrol may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
CiprofloxacinPalmidrol may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
CisplatinThe risk or severity of adverse effects can be increased when Palmidrol is combined with Cisplatin.Approved
Citric AcidPalmidrol may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Palmidrol is combined with Clobetasol.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Palmidrol is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Palmidrol is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Palmidrol is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Palmidrol is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Palmidrol.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Palmidrol.Vet Approved
CloranololPalmidrol may decrease the antihypertensive activities of Cloranolol.Experimental
ColesevelamColesevelam can cause a decrease in the absorption of Palmidrol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Palmidrol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Palmidrol is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Palmidrol is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Palmidrol is combined with Cortisone acetate.Approved, Investigational
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Palmidrol.Approved, Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Palmidrol.Experimental
CyclosporinePalmidrol may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilatePalmidrol may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinPalmidrol may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidPalmidrol may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanPalmidrol may increase the anticoagulant activities of Darexaban.Investigational
DeferasiroxThe risk or severity of adverse effects can be increased when Palmidrol is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Palmidrol is combined with Deflazacort.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Palmidrol is combined with Delapril.Experimental
DesipraminePalmidrol may decrease the antihypertensive activities of Desipramine.Approved, Investigational
DesirudinPalmidrol may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Palmidrol is combined with Desmopressin.Approved
DesonideThe risk or severity of adverse effects can be increased when Palmidrol is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Palmidrol is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Palmidrol is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Palmidrol is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Palmidrol is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Palmidrol is combined with Dexamethasone isonicotinate.Vet Approved
DexibuprofenThe risk or severity of adverse effects can be increased when Palmidrol is combined with Dexibuprofen.Approved, Investigational
DextranPalmidrol may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
DibekacinPalmidrol may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
Dibotermin alfaThe risk or severity of adverse effects can be increased when Palmidrol is combined with Dibotermin alfa.Approved, Investigational
DicoumarolPalmidrol may increase the anticoagulant activities of Dicoumarol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Palmidrol.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Palmidrol is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Palmidrol is combined with Diflunisal.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Palmidrol is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Palmidrol is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Palmidrol.Approved
DihydrostreptomycinPalmidrol may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Palmidrol.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Palmidrol.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Palmidrol.Approved
DrospirenonePalmidrol may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Palmidrol is combined with Droxicam.Withdrawn
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Palmidrol.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Palmidrol.Investigational
Edetic AcidPalmidrol may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanPalmidrol may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Palmidrol is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Palmidrol is combined with Enalaprilat.Approved
EnoxacinPalmidrol may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinPalmidrol may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Palmidrol.Experimental
EpanololPalmidrol may decrease the antihypertensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Palmidrol.Approved
EpitizideThe therapeutic efficacy of Epitizide can be decreased when used in combination with Palmidrol.Experimental
EplerenonePalmidrol may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Palmidrol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Palmidrol.Approved
EquileninThe risk or severity of adverse effects can be increased when Palmidrol is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Palmidrol is combined with Equilin.Approved
EsatenololPalmidrol may decrease the antihypertensive activities of Esatenolol.Experimental
EsmololPalmidrol may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Palmidrol is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Palmidrol is combined with Estrone sulfate.Approved
Etacrynic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Palmidrol.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Palmidrol is combined with Etanercept.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Palmidrol.Experimental
Ethyl biscoumacetatePalmidrol may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Palmidrol is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Palmidrol is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Palmidrol.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Palmidrol is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Palmidrol.Investigational, Nutraceutical
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Palmidrol.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Palmidrol.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Palmidrol.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Palmidrol is combined with Fenoprofen.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Palmidrol.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Palmidrol.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Palmidrol.Experimental
Ferulic acidPalmidrol may increase the anticoagulant activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Palmidrol.Approved, Investigational
Fish oilThe risk or severity of adverse effects can be increased when Palmidrol is combined with Fish oil.Approved, Nutraceutical
FleroxacinPalmidrol may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Palmidrol.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Palmidrol is combined with Fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Palmidrol is combined with Fludrocortisone.Approved, Investigational
FluindionePalmidrol may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumequinePalmidrol may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Palmidrol is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Palmidrol is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Palmidrol.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Palmidrol.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Palmidrol is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Palmidrol is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Palmidrol is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Palmidrol is combined with Fluorometholone.Approved, Investigational
FluprednideneThe risk or severity of adverse effects can be increased when Palmidrol is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Palmidrol is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Palmidrol.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Palmidrol is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Palmidrol is combined with Flurbiprofen.Approved, Investigational
FluticasoneThe risk or severity of adverse effects can be increased when Palmidrol is combined with Fluticasone.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Palmidrol is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Palmidrol is combined with Fluticasone propionate.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Palmidrol.Approved, Nutraceutical, Vet Approved
FondaparinuxPalmidrol may increase the anticoagulant activities of Fondaparinux.Approved, Investigational
Fondaparinux sodiumPalmidrol may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Palmidrol.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Palmidrol is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Palmidrol is combined with Fosinopril.Approved
FramycetinPalmidrol may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideThe therapeutic efficacy of Furosemide can be decreased when used in combination with Palmidrol.Approved, Vet Approved
GabexatePalmidrol may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinPalmidrol may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinPalmidrol may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Palmidrol.Approved, Withdrawn
GemifloxacinPalmidrol may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinPalmidrol may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinPalmidrol may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1APalmidrol may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GinsengThe risk or severity of adverse effects can be increased when Palmidrol is combined with Ginseng.Approved, Investigational, Nutraceutical
GrepafloxacinPalmidrol may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Palmidrol.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Palmidrol is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Palmidrol is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Palmidrol is combined with HE3286.Investigational
HeparinPalmidrol may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Palmidrol.Investigational
HydralazinePalmidrol may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Palmidrol.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Palmidrol is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Palmidrol.Approved, Investigational
Hygromycin BPalmidrol may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Palmidrol is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Palmidrol is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Palmidrol.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Palmidrol.Approved, Investigational
IcosapentThe risk or severity of adverse effects can be increased when Palmidrol is combined with Icosapent.Approved, Nutraceutical
IdraparinuxPalmidrol may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Palmidrol.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Palmidrol is combined with Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Palmidrol.Experimental
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Palmidrol.Approved
IndenololPalmidrol may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Palmidrol.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Palmidrol is combined with Indomethacin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Palmidrol.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Palmidrol.Approved, Investigational
IsepamicinPalmidrol may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Palmidrol.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Palmidrol is combined with Istaroxime.Investigational
KanamycinPalmidrol may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Palmidrol.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Palmidrol is combined with Ketoprofen.Approved, Vet Approved
LabetalolPalmidrol may decrease the antihypertensive activities of Labetalol.Approved
LandiololPalmidrol may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Palmidrol.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Palmidrol.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Palmidrol.Approved, Investigational
LepirudinPalmidrol may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanPalmidrol may increase the anticoagulant activities of Letaxaban.Investigational
LevobetaxololPalmidrol may decrease the antihypertensive activities of Levobetaxolol.Approved, Investigational
LevobunololPalmidrol may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinPalmidrol may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Palmidrol.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Palmidrol is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Palmidrol.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Palmidrol.Approved
LomefloxacinPalmidrol may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Palmidrol.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Palmidrol is combined with Lornoxicam.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Palmidrol.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Palmidrol is combined with Loteprednol.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Palmidrol.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Palmidrol.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Palmidrol is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Palmidrol.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Palmidrol is combined with Magnesium salicylate.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Palmidrol.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Palmidrol is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Palmidrol is combined with Meclofenamic acid.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Palmidrol is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Palmidrol is combined with Mefenamic acid.Approved
MelagatranPalmidrol may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Palmidrol is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Palmidrol is combined with Meloxicam.Approved, Vet Approved
MepindololPalmidrol may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineThe risk or severity of adverse effects can be increased when Palmidrol is combined with Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Palmidrol.Approved, Investigational, Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Palmidrol.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Palmidrol.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Palmidrol is combined with Methylprednisolone.Approved, Vet Approved
MetipranololPalmidrol may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Palmidrol.Approved
MetoprololPalmidrol may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MicronomicinPalmidrol may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MifamurtideThe therapeutic efficacy of Mifamurtide can be decreased when used in combination with Palmidrol.Approved, Experimental
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Palmidrol.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Palmidrol.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Palmidrol is combined with Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Palmidrol.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Palmidrol is combined with Mometasone.Approved, Vet Approved
MoxifloxacinPalmidrol may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Palmidrol.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Palmidrol.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Palmidrol is combined with Nabumetone.Approved
NadololPalmidrol may decrease the antihypertensive activities of Nadolol.Approved
NadroparinPalmidrol may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatPalmidrol may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Palmidrol.Approved
Nalidixic AcidPalmidrol may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Palmidrol is combined with Naproxen.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Palmidrol is combined with NCX 1022.Investigational
NeaminePalmidrol may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololPalmidrol may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NemonoxacinPalmidrol may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinPalmidrol may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Palmidrol is combined with Nepafenac.Approved, Investigational
NetilmicinPalmidrol may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Palmidrol.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Palmidrol is combined with Niflumic Acid.Approved
NimesulideThe risk or severity of adverse effects can be increased when Palmidrol is combined with Nimesulide.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Palmidrol.Investigational
NorfloxacinPalmidrol may increase the neuroexcitatory activities of Norfloxacin.Approved
OfloxacinPalmidrol may increase the neuroexcitatory activities of Ofloxacin.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Palmidrol is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Palmidrol.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Palmidrol.Approved
OlsalazinePalmidrol may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when Palmidrol is combined with Omacetaxine mepesuccinate.Approved, Investigational
OmapatrilatThe risk or severity of adverse effects can be increased when Palmidrol is combined with Omapatrilat.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Palmidrol.Vet Approved
OtamixabanPalmidrol may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Palmidrol is combined with Oxaprozin.Approved
Oxolinic acidPalmidrol may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololPalmidrol may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Palmidrol.Approved, Withdrawn
PamidronateThe risk or severity of adverse effects can be increased when Palmidrol is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Palmidrol is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Palmidrol is combined with Parecoxib.Approved
ParomomycinPalmidrol may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Palmidrol.Approved, Investigational
PazufloxacinPalmidrol may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinPalmidrol may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololPalmidrol may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitratePalmidrol may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfatePalmidrol may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Palmidrol is combined with Perindopril.Approved
PhenindionePalmidrol may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonPalmidrol may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Palmidrol is combined with Phenylbutazone.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Palmidrol.Approved, Investigational
PindololPalmidrol may decrease the antihypertensive activities of Pindolol.Approved, Investigational
Pipemidic acidPalmidrol may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PiretanideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Palmidrol.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Palmidrol.Approved, Investigational
Piromidic acidPalmidrol may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Palmidrol is combined with Piroxicam.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Palmidrol.Experimental
PitolisantThe risk or severity of adverse effects can be increased when Palmidrol is combined with Pitolisant.Approved, Investigational
Platelet Activating FactorPalmidrol may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinPalmidrol may decrease the excretion rate of Plazomicin which could result in a higher serum level.Investigational
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Palmidrol.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Palmidrol is combined with Pomalidomide.Approved
Potassium CitratePalmidrol may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational, Vet Approved
PractololPalmidrol may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Palmidrol.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Palmidrol.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Palmidrol is combined with Prasterone.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Palmidrol is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Palmidrol is combined with Prednicarbate.Approved, Investigational
PrednisoloneThe risk or severity of adverse effects can be increased when Palmidrol is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Palmidrol is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Palmidrol is combined with Pregnenolone.Approved, Experimental, Investigational
ProbenecidThe serum concentration of Palmidrol can be increased when it is combined with Probenecid.Approved, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Palmidrol.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Palmidrol.Approved, Investigational
PropafenonePalmidrol may decrease the antihypertensive activities of Propafenone.Approved
PropranololPalmidrol may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Palmidrol.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Palmidrol.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Palmidrol.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Palmidrol.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Palmidrol.Vet Approved
Protein CPalmidrol may increase the anticoagulant activities of Protein C.Approved
Protein S humanPalmidrol may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydePalmidrol may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinPalmidrol may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Palmidrol.Investigational
PuromycinPalmidrol may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Palmidrol is combined with Quinapril.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Palmidrol.Approved
RamiprilThe risk or severity of adverse effects can be increased when Palmidrol is combined with Ramipril.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Palmidrol is combined with Rescinnamine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Palmidrol is combined with Resveratrol.Approved, Experimental, Investigational
ReviparinPalmidrol may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinPalmidrol may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Palmidrol is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Palmidrol is combined with Risedronate.Approved, Investigational
RivaroxabanPalmidrol may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Palmidrol is combined with Rofecoxib.Approved, Investigational, Withdrawn
RosoxacinPalmidrol may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RufloxacinPalmidrol may increase the neuroexcitatory activities of Rufloxacin.Experimental
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Palmidrol.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Palmidrol.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Palmidrol is combined with Salicylic acid.Approved, Investigational, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Palmidrol is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Palmidrol.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Palmidrol.Investigational
SarilumabSarilumab may increase the immunosuppressive activities of Palmidrol.Approved, Investigational
SeliciclibThe risk or severity of adverse effects can be increased when Palmidrol is combined with Seliciclib.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Palmidrol.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Palmidrol.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Palmidrol.Investigational
SisomicinPalmidrol may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinPalmidrol may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
Sodium CitratePalmidrol may increase the anticoagulant activities of Sodium Citrate.Approved, Investigational
Sodium phosphateSodium phosphate may increase the nephrotoxic activities of Palmidrol.Approved
SotalolPalmidrol may decrease the antihypertensive activities of Sotalol.Approved
SparfloxacinPalmidrol may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpiraprilThe risk or severity of adverse effects can be increased when Palmidrol is combined with Spirapril.Approved
SpironolactonePalmidrol may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Palmidrol.Investigational
StreptomycinPalmidrol may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Palmidrol is combined with Sulfasalazine.Approved
SulindacThe risk or severity of adverse effects can be increased when Palmidrol is combined with Sulindac.Approved, Investigational
SulodexidePalmidrol may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Palmidrol.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Palmidrol is combined with Suprofen.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Palmidrol.Experimental
TacrolimusPalmidrol may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Palmidrol.Approved
TalinololPalmidrol may decrease the antihypertensive activities of Talinolol.Investigational
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Palmidrol.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Palmidrol.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Palmidrol is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Palmidrol is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Palmidrol.Approved, Investigational
TemafloxacinPalmidrol may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Palmidrol is combined with Temocapril.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Palmidrol.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Palmidrol is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Palmidrol is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Palmidrol.Vet Approved
TerbutalinePalmidrol may decrease the antihypertensive activities of Terbutaline.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Palmidrol.Approved
TertatololPalmidrol may decrease the antihypertensive activities of Tertatolol.Experimental
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Palmidrol is combined with Tiaprofenic acid.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Palmidrol is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololPalmidrol may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Palmidrol.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Palmidrol is combined with Tixocortol.Approved, Withdrawn
TobramycinPalmidrol may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Palmidrol.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Palmidrol is combined with Tolmetin.Approved
TorasemideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Palmidrol.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Palmidrol is combined with Trandolapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Palmidrol.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Palmidrol.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Palmidrol.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Palmidrol is combined with Triamcinolone.Approved, Vet Approved
TriamterenePalmidrol may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Palmidrol.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Palmidrol.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Palmidrol.Investigational
Trolamine salicylateThe risk or severity of adverse effects can be increased when Palmidrol is combined with Trolamine salicylate.Approved
TrovafloxacinPalmidrol may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinPalmidrol may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Palmidrol is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Palmidrol.Approved, Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Palmidrol is combined with Valdecoxib.Approved, Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Palmidrol.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Palmidrol.Approved
WarfarinPalmidrol may increase the anticoagulant activities of Warfarin.Approved
XimelagatranPalmidrol may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Palmidrol.Approved, Investigational
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Palmidrol.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Palmidrol is combined with Zofenopril.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when Palmidrol is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Palmidrol.Withdrawn
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB0002100
KEGG Drug
D08328
KEGG Compound
C16512
ChemSpider
4509
BindingDB
29083
ChEBI
71464
ChEMBL
CHEMBL417675
Wikipedia
Palmitoylethanolamide

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00136 mg/mLALOGPS
logP5.74ALOGPS
logP4.98ChemAxon
logS-5.3ALOGPS
pKa (Strongest Acidic)15.46ChemAxon
pKa (Strongest Basic)-1.3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area49.33 Å2ChemAxon
Rotatable Bond Count16ChemAxon
Refractivity90.09 m3·mol-1ChemAxon
Polarizability40.05 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0w29-7179000000-22766d934944105dccf9
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-03dl-9130000000-c6d2bfc2e68da1f5b0d2
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-01ox-9410000000-d078025cabaaf62c59b9
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0002-1090000000-5224a67dd0daaea79191
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-01ot-5090000000-dd9396934201d60f5af2
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0006-9010000000-d5bf936e945bfc965dfe

Taxonomy

Classification
Not classified

Drug created on May 22, 2018 11:59 / Updated on June 02, 2018 08:58